Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ETCompany ParticipantsBreno Toledo Pires de Oliveira - Chief ...

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...

(Billable Hours is Reuters' weekly report on lawyers and money. Please send tips or suggestions to ...

Greenhouse gas emissions related to pharmaceutical consumption increased by 77% over the past 24 years, according to a Leiden ...

Based on data reported through the CDP 2024 Assessment Questionnaire, WuXi Biologics achieved a score of "A" for Water Security, standing out among over 25,000 companies evaluated.

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025. MBX 1416 Phase 2 trial in patients with post-bariatric ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Operator: Good afternoon, and welcome to the Evoke Pharma, Inc. Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently, all callers have been placed in a listen-only mode.

Warning that the state’s health care system is “falling apart,” the Senate’s point person on the topic said Thursday that she wants to rein in for-profit and private equity entities as well as give ...